½ÃÀ庸°í¼­
»óǰÄÚµå
1631164

¼¼°èÀÇ ¿Ü¿ë¾à ½ÃÀå - ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Åõ¿© °æ·Îº°, À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)

Topical Drugs Market Size, Share & Trends Analysis Report By Route Of Administration (Dermal, Ophthalmic, Rectal, Vaginal, Nasal), By Type (Semi-solid, Transdermal), By End Use, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿Ü¿ë¾à ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ

Grand View Research Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è ¿Ü¿ë¾à ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 2,693¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù.

ÀÌ »ê¾÷Àº 2025-2030³â Áß¿¡ CAGR 6.0%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »ê¾÷ ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ÁÖ¿ä ±â¾÷ °£ÀÇ Àü·«Àû Á¦ÈÞ¿Í ÇÔ²² ÇǺΠÁúȯÀÇ À¯º´·ü Áõ°¡¸¦ Æ÷ÇÔÇÕ´Ï´Ù. °Ç¼±, ¾ÆÅäÇÇ ÇǺο°, ½ÀÁø°ú °°Àº ÇǺΠ°¨¿°ÀÇ À¯º´·ü Áõ°¡´Â ´«°ú ±Í Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È °æÇÇ ¶Ç´Â °æÇÇ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 10¿ù, AbbVie Inc.´Â ³ë¾È Ä¡·á¿ë ÇÇ·ÎÄ«¸£ÇÉ ¿°»ê¿° Á¡¾È¾× VuityÀÇ FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù.

¶ÇÇÑ NCBI¿¡ µû¸£¸é °Ç¼±ÀÇ À¯º´·üÀº À¯·´¿¡¼­´Â °ÅÀÇ 1.92%, ºÏ¹Ì¿¡¼­´Â 1.5%ÀÔ´Ï´Ù. ÇǺÎÁúȯÀ» Ä¡·áÇÏ´Â ¿Ü¿ë¾àÀÇ ¹ß¸Åµµ ÇÇºÎ¾à ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 9¿ù, ij³ª´Ù Bausch Health´Â °Ç¼± ȯÀÚ¸¦ À§ÇÑ »õ·Î¿î ÇװǼ±Á¦ Duobrii ·Î¼ÇÀ» Ãâ½ÃÇß½À´Ï´Ù. ±â¼úÀÇ Áøº¸¿Í Alcon, Inc. ¹× Novartis AG µî ÁÖ¿ä ±â¾÷ °£ÀÇ ÀμöÇÕº´ Ȱµ¿ Ȱ¼ºÈ­´Â »ê¾÷ÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 6¿ù, Novartis AG´Â Kedalion Therapeutics¸¦ ÀμöÇÏ¿© ¾È°ú¿ë ÀǾàǰÀÇ Á¤È®ÇÑ °æÇÇ Àü´ÞÀ» ÃËÁøÇÏ´Â AcuStream ±â¼úÀ» ȹµæÇß½À´Ï´Ù.

°Ô´Ù°¡ 2022³â 5¿ù¿¡´Â Alcon Inc.°¡ Kala Pharmaceuticals, Inc.·ÎºÎÅÍ ¾È°ú¿Ü¿ë¾àÀÎ Eysuvis(·ÎÅ×ÇÁ·¹µå³î¿¡Å¸º»»ê Çöʾ×)¸¦ ÀμöÇÏ¿© ¾È±¸°ÇÁ¶Áõ Ä¡·áÀÇ ±âÁ¸ Æ÷Æ®Æú¸®¿À¿¡ Ãß°¡Çß½À´Ï´Ù. ¿¹¸¦ µé¾î WHO¿¡ µû¸£¸é Àü ¼¼°èÀûÀ¸·Î ¿¬°£ 1,100¸¸ °ÇÀÇ È­»óÀÌ ¹ß»ýÇϰí ÀÖÀ¸¸ç, ±× Áß ¾à 18¸¸ °ÇÀÌ »ç¸ÁÇϰí ÀÖ´Ù°í ÇÕ´Ï´Ù. È­»óÀÇ Ä¡·á¿¡´Â ¼úÆÄ´ÙÀ̾ÆÁø Å©¸², ºñ½º¹«Æ® ÇÔħ ¼®À¯ °ÅÁî, Áú»ê¼¼·ý, ¾Æ¼¼Æ®»ê¸¶Æä³ªÀ̵å, ³ª³ë°áÁ¤ Àº µî ´Ù¾çÇÑ ¿Ü¿ëÁ¦°¡ »ç¿ëµË´Ï´Ù.

¿Ü¿ë¾à ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ¾à¹° Àü´ÞÀÌ ½ÃÀåÀ» µ¶Á¡ÇßÀ¸¸ç 2024³â¿¡´Â 54.1%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ¹Ý°íÇü Á¦Á¦´Â 2024³â ¸ÅÃâ Á¡À¯À² 61.9%·Î ½ÃÀåÀ» ¼±µµÇß½À´Ï´Ù.
  • º´¿ø Ŭ¸®´ÐÀº 2024³â 38.9%·Î ÃÖ´ë ÆÇ¸Å Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â Àü¹®ÀûÀÎ °³ÀÔÀÌ ÇÊ¿äÇÑ ÇǺÎÁúȯ°ú ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù.
  • ºÏ¹ÌÀÇ ¿Ü¿ë¾à ½ÃÀåÀº ÇǺÎÁúȯÀÇ ³ôÀº À¯º´·ü, ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¿Õ¼ºÇÑ ÅõÀÚ°¡ °ßÀÎÇØ 2024³â ¼¼°è ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¿Ü¿ë¾à ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅëÀÇ Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ºñÁî´Ï½º ȯ°æ ºÐ¼®
    • »ê¾÷ ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTLE ºÐ¼®

Á¦4Àå ¿Ü¿ë¾à ½ÃÀå : Åõ¿©°æ·Î ºñÁî´Ï½º ºÐ¼®

  • Åõ¿© °æ·Îº° ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
  • Åõ¿© °æ·Î ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, Åõ¿© °æ·Îº°, 2018-2030³â
  • °æÇÇ ¾à¹° Àü´Þ
  • ¾È°ú ¾à¹° Àü´Þ
  • Á÷Àå³» ¾à¹° Àü´Þ
  • Áú³» ¾à¹° Àü´Þ
  • ºñ°­³» ¾à¹° Àü´Þ

Á¦5Àå ¿Ü¿ë¾à ½ÃÀå : À¯Çü ºñÁî´Ï½º ºÐ¼®

  • À¯Çüº° ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
  • À¯Çü ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, À¯Çüº°, 2018-2030³â
  • ¹Ý°íÇü Á¦Á¦
  • ¾×ü Á¦Çü
  • °íÇü Á¦Á¦
  • °æÇÇ Èí¼ö Á¦Ç°

Á¦6Àå ¿Ü¿ë¾à ½ÃÀå : ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

  • ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
  • ÃÖÁ¾ ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
  • ÀçÅÃÄ¡·á
  • º´¿ø ¹× Ŭ¸®´Ð
  • È­»ó ¼¾ÅÍ
  • ±âŸ ½Ã¼³

Á¦7Àå ¿Ü¿ë¾à ½ÃÀå : Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â°ú 2030³â
  • Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â
  • ºÏ¹Ì
    • ±¹°¡º°, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ±¹°¡º°, 2018-2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • µ§¸¶Å©
    • ½º¿þµ§
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ±¹°¡º°, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ±¹°¡º°, 2018-2030³â
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ±¹°¡º°, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • Âü°¡ÀÚ °³¿ä
  • ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´× ºÐ¼®
  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ/»óÀå ±â¾÷
    • Bayer AG
    • Cipla
    • GSK plc
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Bausch Health Companies Inc.
    • Hisamitsu Pharmaceuticals Co., Inc.
    • Merck KGaA
    • GLENMARK PHARMACEUTICALS LTD.
    • MedPharm Ltd.
JHS 25.03.04

Topical Drugs Market Growth & Trends:

The global topical drugs market size is expected to reach USD 269.3 billion by 2030, according to a new report by Grand View Research Inc. The industry is expected to grow at a CAGR of 6.0% from 2025 to 2030. The key factors contributing to the industry growth include the increased prevalence of skin disorders coupled with strategic collaborations between key players. The increasing prevalence of skin infections, such as psoriasis, atopic dermatitis, and eczema, coupled with the rising demand for eye and ear therapies is expected to drive the demand for transdermal or dermal medicines during the forecast period. For instance, in October 2021, AbbVie Inc. received FDA approval for Vuity, a pilocarpine HCl ophthalmic solution for treating presbyopia.

In addition, according to the NCBI, the prevalence of psoriasis is nearly 1.92% and 1.5% among European and North American populations. The launch of topical medicines to treat skin diseases is also anticipated to propel the demand for dermal drugs. For instance, in September 2020, Bausch Health, Canada launched a novel antipsoriatic agent, Duobrii lotion for psoriasis patients.Advancements in technology and increased acquisitions and mergers activities among key players, such as Alcon, Inc. and Novartis AG, are anticipated to boost the industry's growth. For instance, in June 2022, Novartis AG acquired Kedalion Therapeutics, thereby acquiring AcuStream technology to facilitate accurate dermal delivery of ophthalmic medicines.

Moreover, in May 2022, Alcon Inc. acquired Eysuvis (loteprednol etabonate suspension) for topical ophthalmic use from Kala Pharmaceuticals, Inc., thereby adding to its existing portfolio of dry eye drugs.A high incidence of burn injuries is expected to render high utilization of topical medicines in treating burn injuries. For instance, according to the WHO, an estimated 11 million burn injuries occur annually worldwide, out of which about 180,000 cases are fatal. Various topical agents are used in treating burn injuries including silver sulfadiazine cream, bismuth-impregnated petroleum gauze, cerium nitrate, mafenide acetate, and nanocrystalline silver among others.

Topical Drugs Market Report Highlights:

  • Dermal drug delivery dominated the market and accounted for a share of 54.1% in 2024, fueled by its capacity to offer targeted treatment, user-friendly application, and improved patient compliance.
  • Semi-solid formulations led the market with a revenue share of 61.9% in 2024 due to their versatility, ease of use, and effectiveness in delivering active ingredients directly to the skin.
  • Hospitals & clinics held the largest revenue share of 38.9% in 2024, driven by the growing prevalence of skin disorders and chronic diseases necessitating professional intervention.
  • North America topical drugs market dominated the global market in 2024, driven by a high prevalence of skin disorders, advanced healthcare infrastructure, and robust investments in research and development.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Route of Administration
    • 1.2.2. Type
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Topical Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Topical Drugs Market: Route of Administration Business Analysis

  • 4.1. Route of Administration Market Share, 2024 & 2030
  • 4.2. Route of Administration Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 4.4. Dermal Drug Delivery
    • 4.4.1. Dermal Drug Delivery Market, 2018 - 2030 (USD Million)
  • 4.5. Ophthalmic Drug Delivery
    • 4.5.1. Ophthalmic Drug Delivery Market, 2018 - 2030 (USD Million)
  • 4.6. Rectal Drug Delivery
    • 4.6.1. Rectal Drug Delivery Market, 2018 - 2030 (USD Million)
  • 4.7. Vaginal Drug Delivery
    • 4.7.1. Vaginal Drug Delivery Market, 2018 - 2030 (USD Million)
  • 4.8. Nasal Drug Delivery
    • 4.8.1. Nasal Drug Delivery Market, 2018 - 2030 (USD Million)

Chapter 5. Topical Drugs Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Semi-solid Formulations
    • 5.4.1. Semi-solid Formulations Market, 2018 - 2030 (USD Million)
    • 5.4.2. Creams
      • 5.4.2.1. Creams Market, 2018 - 2030 (USD Million)
    • 5.4.3. Ointments
      • 5.4.3.1. Ointments Market, 2018 - 2030 (USD Million)
    • 5.4.4. Lotions
      • 5.4.4.1. Lotions Market, 2018 - 2030 (USD Million)
    • 5.4.5. Gel
      • 5.4.5.1. Gel Market, 2018 - 2030 (USD Million)
    • 5.4.6. Pastes
      • 5.4.6.1. Pastes Market, 2018 - 2030 (USD Million)
  • 5.5. Liquid Formulations
    • 5.5.1. Liquid Formulations Market, 2018 - 2030 (USD Million)
    • 5.5.2. Suspensions
      • 5.5.2.1. Suspensions Market, 2018 - 2030 (USD Million)
    • 5.5.3. Solutions
      • 5.5.3.1. Solutions Market, 2018 - 2030 (USD Million)
  • 5.6. Solid Formulations
    • 5.6.1. Solid Formulations Market, 2018 - 2030 (USD Million)
    • 5.6.2. Powders
      • 5.6.2.1. Powders Market, 2018 - 2030 (USD Million)
    • 5.6.3. Suppositories
      • 5.6.3.1. Suppositories Market, 2018 - 2030 (USD Million)
  • 5.7. Transdermal Products
    • 5.7.1. Transdermal Products Market, 2018 - 2030 (USD Million)
    • 5.7.2. Transdermal Patches
      • 5.7.2.1. Transdermal Patches Market, 2018 - 2030 (USD Million)
    • 5.7.3. Transdermal Semi-Solids
      • 5.7.3.1. Transdermal Semi-Solids Market, 2018 - 2030 (USD Million)

Chapter 6. Topical Drugs Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Home Care Settings
    • 6.4.1. Home Care Settings Market, 2018 - 2030 (USD Million)
  • 6.5. Hospitals & Clinics
    • 6.5.1. Hospitals & Clinics Market, 2018 - 2030 (USD Million)
  • 6.6. Burn Centers
    • 6.6.1. Burn Centers Market, 2018 - 2030 (USD Million)
  • 6.7. Other Facilities
    • 6.7.1. Other Facilities Market, 2018 - 2030 (USD Million)

Chapter 7. Topical Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.4. North America
    • 7.4.1. North America Topical Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Topical Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Topical Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Topical Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Topical Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Topical Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Bayer AG
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Cipla
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. GSK plc
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Johnson & Johnson Services, Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Novartis AG
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Bausch Health Companies Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Hisamitsu Pharmaceuticals Co., Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Merck KGaA
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. GLENMARK PHARMACEUTICALS LTD.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. MedPharm Ltd.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦